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Objective: One approach to identifying HIV-1 vaccine candidates is to dissect the natu-
ral antiviral immune response in treatment-naïve individuals infected for over ten years,
considered slow progressor patients (SPs). It is suspected that SP plasma has strongly neu-
tralizing antibodies (NAb) targeting speciﬁc HIV viral epitopes.
Methods: NAbs levels of 11 HIV-1-infected SPs were detected by PBMC-based neutralization
assays. To investigate SP NAb epitope, this study used a biopanning approach to obtain
mimotopes of HIV-1 that were recognized by SP plasma NAbs. IgG was puriﬁed from high-
titer NAb SP plasma, and used as the ligand for three rounds of biopanning to select
HIV-speciﬁc mimotopes from a phage-displayed random peptide library. Double-antibody
sandwich ELISA, competitive inhibition assays, and peptide sequence analysis were used to
evaluate the characteristics of phage-borne mimotopes.
Results: SPs had signiﬁcantly more plasma neutralizing activity than typical progressors
(TPs) (p = 0.04). P2 and P9 plasma,which have highest-titer HIV-NAb,were selected as ligands
for biopanning. After three rounds of biopanning, 48 phage cloneswere obtained, ofwhich 22
cloneswere consistentwith requirement, bindingwithHIV-1 positive plasma andunbinding
withHIV-1 negative plasma. Comparedwith linearHIV-1 protein sequence andHIV-1 protein
structure ﬁles, only 12 clones were possible linear mimotopes of NAbs. In addition, the C40
clone located in gp41 CHR was found to be a neutralizing epitope, which could inhibit pooled
HIV-1 positive plasma reaction.ng of rum IgG can yield mimotopes of HIV-1-related antigen epitopes.Conclusion: BiopanniThismethodology provide
actions and furthers NAb
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ntroduction
collaborative global effort is ongoing to develop an effective
uman immunodeﬁciency virus (HIV) vaccine.1–4 However,
IV-1 vaccine design has faced numerous difﬁculties. The
ain problem is the ability of HIV to rapidly generate mutants
esistant to immune responses. Considering the complexity of
IV-1 replication and pathogenesis, it is widely acknowledged
hat an HIV-1 vaccine, in order to be effective, should include
ultiple antigens and should be able to generate strong and
road neutralizing antibodies (NAbs), as well as cell-mediated
mmune responses.
NAbs are considered a key component of protective vac-
ines against HIV-1; however, despite tremendous efforts,
accination attempts have thus far failed to induce broad
eutralization activity. At present, only a small number of
roadly monoclonal NAbs have been isolated from HIV-
ositive individuals.5 These are the few NAbs that have
xhibited potent and broad HIV-1-neutralizing activity in vitro
nd have been shown to prevent HIV-1 infection in animal
odels.6–8 Of these isolated antibodies, four antibodies in par-
icular, IgG1b12, 2G12, 2F5, and 4E10, have been proven to be
he most effective.9–13 Recently, these NAbs have been admin-
stered in acutely and chronically HIV-1-infected patients in
rder to assess their potential to delay viral rebound after
tructured treatment interruption.14,15
The ability to discover immunogens that are able to elicit
Abs canbe facilitatedby the explorationof the interactions of
hese antibodies with the HIV-1 envelope glycoprotein (Env).6
eanwhile, increased understanding of NAb epitopes may
elp to design immunogens capable of inducing such anti-
odies upon immunization. The identiﬁcation of new broadly
ross-reactive HIV-1 NAbs and their conserved epitopes is
herefore of obvious importance for the development of HIV
rugs and vaccines. Many antibodies directly target the HIV-1
nv, because they are the only virus-encoded determinants
hat are present on the virus surface. Env is comprised of
wo glycoproteins, gp120 and gp41, which mediate cell fusion
n the ﬁrst step of HIV-1 infection. Antibodies targeting con-
erved regions of gp120 and gp41 may be able to neutralize a
ide array of circulating HIV-1 isolates and therefore consti-
ute potential targets for therapeutic intervention.16 A vaccine
ould represent a strategy to induce high levels of NAbs with
redeﬁned epitope-speciﬁcity against HIV-1.
Natural infection with HIV-1 generates many virus-speciﬁc
ntibodies, but most are non-NAbs.17 Interestingly, a group
f HIV-infected patients has been able to control the infec-
ion without antiviral therapy, and have been termed slow
rogressors (SPs). SP patients do not show any evidence of
mmunological deterioration or clinical symptoms of immu-
odeﬁciency despite being infected for over ten years without
ny antiretroviral therapy. Multiple factors have been reported
o contribute to the SP status, including deletions in viral reg-
latory genes or the CCR5 coreceptor gene, as well as several
mmunological factors. Studies have reported that SP plasma
acilitates neutralization of primary HIV-1 isolates more effec-
ively than plasma from HIV-1 typical progressors (TPs).18
oreover, previous studies by the authors have shown that the
lasmaNAb titer of SPs is higher than that of TPs (unpublished2;16(6):510–516 511
data). If NAbs in SPs are indeed involved in delaying disease
progression, a greater comprehension of their epitopes might
assist in designing immunogens. SP sera are also rich in virus-
speciﬁc antibodies, which is advantageous for the process of
biopanning.
Biopanning is a powerful and versatile approach that
allows for speciﬁc desirable epitope-antibody interaction.19,20
Biopanning commonly requires the iterative application of
phage display technology, which due to its screening capac-
ity and broad applicability occupies a central role in the study
of protein-protein interactions.21–23 The power of phage dis-
play lies in the direct physical linkage between a phenotype
and its genotype. A library of bacteriophages, each encoding
a random short peptide that is displayed on the viral surface,
is allowed to interact with a deﬁned target protein. Through
targeted binding and elution, peptides capable of interac-
ting with the target can be easily selected from a milieu of
millions and identiﬁed by sequencing the DNA encapsulated
in the corresponding phage particle.24–26 Biopanning com-
bines current protein andpeptide expressionandmodiﬁcation
methods with simple microbiological procedures that enable
fast ampliﬁcation of hundreds of selected peptides, which
can be applied to retrieve collections of relevant epitopes and
mimotopes binding to antibodies of interest.
In this study, phage displayed peptide libraries were
screened with IgGs from SP plasma. The objective was to
identify the epitopes of NAbs, as these should represent
immunogens potentially able to indicate antigens that are
capable of inducing antibodies upon immunization for HIV-1
vaccine.
Materials and methods
Study population
Thirty-four HIV-1-infected individuals from Henan province
were enrolled in this study. This studywas conducted in accor-
dance with the Declaration of Helsinki, with the approval
of the Ethics Committee of China Medical University. An
informed consent was obtained from all participants. All
patients acquired HIV-1 infection via contaminated blood
transmission. HIV-1 infection was screened by anti-HIV ELISA
(Vironostika, Organon Tenika – The Netherlands) and con-
ﬁrmed by Western blot (Genelab Diagnostics – Singapore).
Among these patients, 11 were known SPs (with asymp-
tomatic and stable CD4+ T-cell counts ≥ 500 cells/L for at least
ten years), while 23 were TPs (CD4+ T cell counts < 500 cells/L
for at least ﬁve years). Only antiretroviral (ARV) treatment-
naïve patients were included in this study. HIV-1 subtype was
determined by phylogenetic analysis based on sections of env,
pol, and gag regions. All SP and TP patients were infected with
HIV-1 B’-clade. Plasma from HIV-negative individuals samples
were used as anegative control in biopanning andphage ELISA
assays.Neutralization assay
PBMC-based assays using SF33 strains were performed in 96-
well culture plates by incubating virus stockwith serial diluted
i s . 20512 braz j infect d
heat-inactived plasma specimen. Approximately 500 TCID50
in 50L (determined by Spearman-Karber equation assay) of
SF33 were incubated with 50L diluted plasma for 30minutes
at 37 ◦C in a well of a 96-well plate, followed by the addition of
PHA-activated PBMC (1.0× 105 in 100L of complete RPMI 1640
medium). After an overnight incubation at 37 ◦C, 150L of the
culture supernatantwere removed, followed by the addition of
150Lof fresh culturemedium.On the fourthday. 100Lof the
culture supernatant was exchanged with 100L of fresh cul-
ture medium. Seven days after infection initiation, duplicate
samples were harvested for measurement of p24-Ag by ELISA.
IC50 values for patient serum NAb activity were calculated,
and the SP and TP IC50 values were compared by Student’s
t-test.
The PBMCs used for this assay were isolated from healthy
donors by standard density gradient centrifugation with
Histopaque-1077 (Sigma). Isolated cells were plated in 25-cm2
plastic ﬂasks and incubated at 37 ◦C for two hours. Non-
adherent cells were collected and resuspended at 1× 106 cells,
and were stimulated in 10mL RPMI-1640 medium containing
10% FBS, 5g/mL PHA, and 100 U/mL IL-2 (Sigma) by incuba-
tion at 37 ◦C for three days.
Biopanning of phage displayed peptide library
The biopanning of phage-displayed peptide was performed
as described elsewhere.27 Brieﬂy, Dynabeads M-280 Tosy-
lactivated were resuspended by pipetting. Goat anti-human
IgG antibody was dissolved in 0.1M H3BO3 (pH 9.5). Dyn-
abeads were precoated with goat anti-human Fc-speciﬁc
antibody, according to the manufacturer’s instructions, and
were incubated with patient plasma for two hours at room
temperature. Beads were washed six times with PBS/0.1%
Tween-20 and continually rotated overnight at 4 ◦C with 10L
(1.5× 1011–2× 1011 particles) from the original M13 bacte-
riophage peptide libraries displaying linear peptide chains
consisting of 12 amino acids (Ph.D.TM – Phage Display
Peptide Library; New England Biolabs). The next day, the
beads were washed extensively with PBS/0.1% Tween-20, and
bound phages were eluted by pH shift [0.2 Mglycine-HCl
(pH 2.2)/1mg/mL BSA], neutralized with 1M Tris-HCl (pH
9.1). Beads were used for three rounds of selection. Positive
selection was ﬁrst performed with plasma from HIV-infected
patients. Supernatants of the positive selection were ampli-
ﬁed in Escherichia coli ER2783, precipitated overnight at 4 ◦C,
and used for two more rounds of selection. Negative selec-
tion was performed as the third step with pooled plasma from
HIV-negative subjects. The plasma of patients was obtained
respectively from SP patients P2 and P9. Tween-20 concentra-
tions were increased stepwise (0.1, 0.3, 0.5%) during the three
rounds of panning. After the third selection, the phages were
titered and picked randomly. Plaques were picked from plates
with no more than 100 clones for incubating and sequencing.
Ampliﬁed phages were concentrated by PEG/NaCl precipita-
tion and analyzed for speciﬁcity by ELISA. Single-stranded
DNA of positive phage clones (OD values >2.0 control) were
prepared and sequenced to deduce the peptide insert. DNA
sequences encoding the peptides (170bp) were ampliﬁed with
the primers PHD1-(5′-TTC GCA ATT CCT TTA GTG-3′) and
PHD2- (5′-TTT GTC GTC TTT CCA GAC GT-3′). The PHD212;16(6):510–516
primer is recommended for dideoxy sequencing. Phage clone
peptide sequences were determined and analyzed for linear
homology to HIV-1 proteins by local BLAST. Phage peptide
sequences were compared against a reference HIV-1 subtype
B Env protein sequence (B.TH.90.BK132 ACC AY173951), using
the Bioedit program to identify neutralization epitopes.
Detection of HIV-speciﬁc phage clones
Phages displaying mimotopes were subsequently tested with
phage ELISA to conﬁrm HIV speciﬁcity. Nunc-Immuno Max-
isorp 96-well plates (Nalge-Nunc International) were coated
overnight at 4 ◦C with 100L/well of M13 antibody (Pharma-
cia) at a concentration of 10g/mL. The next day, the plates
were blocked with 200L blocking solution of 3% BSA in
PBS for two hours at 37 ◦C, and were washed three times in
an automated plate washer. 100L/well of phages, selected
through biopanning, were added in a 1:1 ratio to wells with
100L/well of a 1:100 dilution of plasma of either pooled HIV-
1 negative controls or pooled HIV-1 positive controls. Mixtures
were performed in triplicate and were incubated overnight
at 4 ◦C. The plates were washed, incubated with 100L/well
HRP-goat anti-human IgG conjugate for one hour at 37 ◦C
developed with ABTS substrate (Pharmacia) for 15minutes at
room temperature, and read at 405nm. Clones that reacted
with HIV-positive serum (OD value >2.0 fold blank control)
were selected for further experimentation, while clones that
reacted with HIV-negative serum (OD value >1.5 fold blank
control) were discarded.
Competition inhibition binding of phage clone
To determine whether phage clones represented mimotopes
of gp41, competitive inhibition assays using gp41 were con-
ducted. Nunc-Immuno Maxisorp 96-well plates were coated
with 100L/well gp41 peptide at concentration of 0.1g/mL,
overnight at 4 ◦C. Thenext day, plateswere blockedwith 200L
blocking solution of 3% BSA in PBS for one hour at 4 ◦C, and
werewashed three timeswith PBST (1%Tween-20). Plateswere
incubated with phage clone, which was diluted four-fold seri-
ally from 1:4 to 1:64, and pooled HIV-positive plasma (1:800)
for two hours at 37 ◦C. Samples were run in duplicate. After
four washes with PBST, 100L of a 1:5000 dilution of HRP-
conjugated goat anti-human IgG was added and incubated for
one hour at 37 ◦C. After four washes with wash buffer, assays
were developed at 37 ◦C for 15 to 30minutes with ready-to-use
TMB substrate, and read at 450nm.
Ampliﬁcation and sequencing of gp41 fragment
HIV-1 RNA fromplasmawas extractedwithQIAampViral DNA
and RNA Mini Kit (Qiagen – Germany), according to the man-
ufacturer’s recommendations. RNA was reverse transcribed
into cDNA with a reverse transcriptase kit (TAKARA – Japan).
Two separate plasmas were obtained from patients P2 and
P9. The HIV-1 gp41 gene (461bp) was ampliﬁed with outer
′primers gp41-1 (5 -TCT TRG GAG CAG CAG GAA GCA CTA TGG
G- 3′HIV-1HXB2 7789-7816nt) and gp41-2 (5′-AAC GAY AAJ GGT
GAR TAT CCC TGC CTAA- 3′HIV-1HXB2 8374-8347nt), and fol-
lowed by nested PCR with inner primers gp41-3 (5′-ACA ATT
braz j infect d i s . 201
Table 1 – Neutralizing activity levels (IC50) in slow
progressor (SPs) and typical progressor (TPs) patients.
Group n IC50 (mean±SD) p-value
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F
pSPs 11 160.33 ± 107.88 0.037
TP 23 87.22 ± 105.33
TT GTC TGG TAT AGT GCA RCA GCA - 3′HIV-1HXB2 7850-
879nt) and gp41-4 (5′-TTA AAC CTA YCA AGC CTC CTA CTA
CA TTA - 3′HIV-1HXB2 8310-8281nt). Puriﬁed PCR products
ere directly sequenced by dideoxy chain termination with
rimers gp41-5 (5′-CAA TTA TTG TCT GGT ATA GTG C-3′, HIV-
HXB2 7851-7872nt) and gp41-6 (5′-CAA GCC TCC TAC TAT CAT
A-3′ HIV-1HXB2, 8300-8281nt), on an automated sequencer 377
Applied Biosystems - USA). DNAStar was used to predict con-
ormational epitopes of the gp41 region. The two HIV-1 gp41
equences used in this analysis containing neutralizing epi-
ope have been submitted to Genbank under the following
ccession IDs: EU569806, EU569820.
esults
eutralizing activity of SP and TP plasma
o conﬁrmNAbs as a likely factor in viral control in SPpatients,
n vitro neutralization assays with SP and TP plasma were per-
ormed and compared. Neutralization assay IC50 values for SP
nd TP groups are shown in Table 1. The neutralizing ability
f SP plasma was signiﬁcantly higher than that of TP patient
lasma. SP patient mean IC50s are summarized in Fig. 1. All SP
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ig. 1 – Neutralizing activity levels (IC50) of 11 sow
rogressors.
Table 2 – Epitopes obtained correlated with neutralizing activity
Location 
B.TH.90 
C8 
719-730 
QTHLPAPRGPDR
TMGFTAPRFPHY
Location 
B.TH.90 
C10 
135-146 
LRNTTNTN
SHALPLTW
Location 
B.TH.90 
C18 
805-816 
SQELKNSAVSLL
LPQTPNSYRSLL
Location 
B.TH.90 
C22 
141-152 
DLRNTTNT
ADRLTGNT
Location 
B.TH.90 
C30 
706-717 
VNRVRQGYSPLS
EPWLDSRYSPLS
Location 
B.TH.90 
C40 
637-649 
NYTGLIYT
YDTRLISK
Location 
B.TH.90 
C48
713-724 
YSPLSFQTHLPA
FSPLHTSTYRPS 
The entire peptide is shown for each clone. Homology amino acid residue2;16(6):510–516 513
plasma samples neutralized the heterologous HIV-1 subtype
B strain SF33. Plasma from SP patients P2 and P9 displayed
strongly neutralizing activity, conﬁrming that NAbs indeed
contributed to strong neutralization in these patients.
Selection of HIV-1 mimotopes clones
Relevant HIV-1-speciﬁc epitopes were investigated through
selectionofmimotopes by biopanning. Biopanningwithphage
libraries screened with immobilized IgG from plasma from
P2 and P9 yielded 48 phage clones, which were analyzed for
speciﬁcity through phage ELISA. Clone selection was based on
reactivity; 38 clones that reacted with the HIV-positive plasma
pool were selected, subsequently, 16 clones of 38 clones that
reacted with the HIV-negative plasma pool were discarded.
Analysis of HIV-1 mimotopes
The 22 phage clone peptide sequences were compared with
linear HIV-1 protein sequence and HIV-1 protein structure
ﬁles. 12 clones were determined to be possible continuous lin-
ear mimotopes of NAbs (Table 2). The remaining ten epitopes
did not align with the reference sequence and may possibly
represent discontinuous epitopes. Of the 12 linear clones, six
clonesmimicked epitopes on the envelope glycoprotein gp120.
Clones 14, 15, and 31 were identical and were located in the
gp120 C1 region. Clone 10 was located in the gp120 V1 loop,
clone 22 occurred in the gp120 C2 region, and clone 23 was
located in the gp120 V4 loop. Another six clones mimicked
epitopes on gp41. Notably, clone 40 had the highest titer by
inhibition ratio against gp41 of all six gp41 clones analyzed
(Fig. 2). The sequence of clone 40 was localized in the gp41
C-terminal heptad repeat.
Cross-reactivity of selected phage groups
In order to identify conserved mimotopes that are capable
of reacting with more than one HIV-positive plasma sam-
ple, phage clones were analyzed for cross-reactivity with a
panel of plasma from HIV progressors by ELISA. The broadest
cross-reactivitywasobserved in thephage clones representing
immunodominant linear mimotopes, such as the gp41 CHR
domain. Due to the fact that the C40 phage clone had a high
inhibition ratio (46.7%)when reactedwithHIV-positive plasma
.
STAE
STAA
Location           
B.TH.90       
C14-15-31   
91-102
ENFXMWTNNMAE
ATSTMWTNYPWN
NSTA
WSVQ
Location 
B.TH.90 
C23 
379-390 
FFCNSTKLFNST
WSPGQQRLHNST
LIEE
LQVS
Location 
B.TH.90 
C43 
720-731 
THLPAPRGPDRP
GHLIALRQPSHQ
s are shaded in grey.
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Fig. 2 – Inhibition ratio of the six phage clones located in
gp41. Clone8, clone18, clone30, clone40, clone43, clone48.
Clones were four-fold serially diluted from 1:4 to 1:64 and
HIV-positive plasma diluted 1:800.
Table 3 – Comparison of C40 peptide sequence with
various subtype sequences.
01_AE.CF.90.90CF11697 NYTNQIYELLTK   
C.CN.x.GX_C_14_AY217546 NYTNTIYRLLED
B.CN.x.RL42_U71182 NYTREIYTLIEE
B.US.x.SUMA20_09_AY223765 NYTSLIYTLLEQ
P2 P9 NYTREIYTLIEE
iﬁed the importance of broadly NAbs in enhancing the controlpools in competition ELISA, the P2 and P9 gp41 fragmentswere
sequenced (Fig. 3). C40 corresponded to a region of the gp41
reference sequence residues 637-648. Compared with other
HIV subtype sequences, the region that C40 mimicked was
found to be relatively conserved (Table 3). In silico predictions
of the gp41 region mimicked by C40 showed that the region
550
B. TH. 90. BK132 ACC AY173951
HA202
HA116
B. TH. 90. BK132 ACC AY173951
HA202
HA116
B. TH. 90. BK132 ACC AY173951
HA202
HA116
560
620 630
690 700
Fig. 3 – Amino acid sequences of the gp41 regions from P2 and P
mimics the region located at B.TH.90 reference sequence residue
50
A
B
C
6
1
4.5
1.7
–1.7
0
0
100 150 200 250 300 350 400 450 500 550
Fig. 4 – The conformational epitopes of gp41 (containC40 YDTRLISKLQVS
was characterized by hydrophobicity and high antigenic index
(Fig. 4).
Discussion
The discovery of novel broadly cross-reactive human mono-
clonal NAbs to various antigens has major implications for
the development of vaccines. Accumulating evidence has clar-of viral replication through cellular immune response. Previ-
ous reports of the presence of NAbs in SPs concluded that the
570 580 590 600
640 650 660 670
9 plasma viral. The C40 sequence is boxed in black and
s 637-648.
600 650 700 750 800
Scale
Beta, Regions - Gamier-Robson
Coil, Regions - Gamier-Robson
Surface probability plot - Emini
Hydrophilicity plot - Kyte-Doolittle
Antigenic index - Jameson-Wolf
Alpha, Regions - Gamier-Robson
C40 637-648aa) predicted by DNAStar software.
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P response is broader in magnitude and breadth than the
P response.18 However, in most of these studies, SP patients
ere compared to patientswith advancedAIDS. Therefore, the
elatively superior neutralization of the SP plasma that was
bserved could be due to the lack of antibodies typically seen
s a symptom of AIDS.
In this study, an experimental strategy that could facil-
tate the selection of high-titer antibodies from SPs was
escribed. Screening of HIV-infected patient plasma with
hage-displayed random libraries can identify peptide mim-
cs of HIV-1 immunodominant epitopes that can extend the
ange of structural or protein-protein interaction studies of
iral epitopes. In this study, phage display and biopanning
ere used in a reverse vaccinology approach to identify anti-
enic epitopes relevant for HIV-1 vaccine development. Eleven
nown SPs who had successfully controlled HIV-1 infection
or more than 10 years were selected for research. Two of
he 11 SP patients with the highest plasma NAb IC50 values
ere chosen for selection and characterization of mimotopes.
hage-displayed peptide libraries with immobilized IgG from
wo SPs were described, and 22 mimotopes were selected to
e analyzed for homology to the HIV-1 Env protein. SP plasma
as used to screen phage libraries for HIV speciﬁcity, result-
ng in the selection of 12 linear mimotopes, which mostly
orresponded to immunodominant epitopes in the HIV-1 Env
omplex proteins gp120 or gp41. The overrepresentation of
nv in isolated mimotopes can be explained by the fact that
he Envs gp120 and gp41 are the only viral proteins exposed
n the exterior of the virus particle; thus, they are the only
roteins that elicit HIV-speciﬁc NAbs in infected individuals.
accine design efforts have thus focused on eliciting broad
Ab response to these two proteins.
The methods used in this study only surveyed linear
pitopes; discontinuous conformational epitopes for broadly
eutralizing activity may have been generated, but were not
onﬁrmed. Conserved linear domains on gp41 have been
bserved, and for this reason gp41 was chosen to survey
pitopes for novel targets for Nabs.28,29 Competition ELISA
howed phage clones that represented epitopes on gp41,
ncluding the high-titer clone C40, which had a high inhi-
ition ratio (46.7%) against a pool of HIV-positive plasma.
consensus motif C40 that mimics the gp41 CHR epitope
as also identiﬁed. The HIV-1 transmembrane subunit gp41
s an important modulator in HIV-1 entry in its host cell
hat contains a hydrophobic, glycine-rich sequence, referred
o as the fusion peptide at its amino terminus. The fusion
eptide region is followed by two heptad repeat sequences
f hydrophobic amino acids (N-terminal heptad repeat and
terminal heptad repeat) that form helical domains with
ydrophobic faces. Packing interactions between these two
egions are critical for membrane fusion.16,20,30–33 In the pre-
airpin intermediate state of gp41, the N-terminal heptad
epeat (N-HR, residues 542–591 of HIV-1 Env) and the C-
erminal heptad repeat (C-HR, residues 628–661) interact with
nother exposed N-HR to form a trimeric coiled-coil.30,34–36
he C40 clone mimicks an epitope on the internal trimeric
oiled-coil of the C-HR.
The present results also suggest that the functionally
mportant gp41 structure is not masked as efﬁciently in SP
iruses, resulting in better recognition and generation of2;16(6):510–516 515
anti-gp41 antibodies with broader neutralizing capacity. For
the conformational epitopes predicted by DNAStar, it was also
observed that the region of gp41 mimicked by C40 was char-
acterized with hydrophobicity and a high antigenic index.
Hence, C40 may be used for further investigation as an engi-
neered immunogenic version of its gp41 epitope. In addition,
C40 was located in the fusion-inhibitor drug enfuvirtide (T20)
target region in the gp41 heptad repeat 1 (HR1) domain.37 T20
is a member of a successful new generation of entry inhibitors
targeting Env gene products. T20 is a synthetic peptide of 36
amino acids derived from a CHR fragment of B subtype HIV-1
gp41, which competes for binding of the NHR and thus blocks
the formation of the hairpin structure that brings the virus
and cell membranes into proximity for fusion. The functional
relevance and utility of conservation of the gp41 region mim-
icked by C40 is illustrated in the broad recognition of C40 as an
antigen by pooled plasma from 12 patients. The authors pro-
pose that a collection of such mimotopes can provide effective
antigen-like characteristics for vaccine development.
In conclusion, the results suggest that neutralizing
responses directed at epitopes like the gp41 CHR epitope
may protect SPs through reasonably potent inhibition of Env-
mediated cell fusion. The results of this study advance the
generation of reliable and high-yield mimotope collections of
HIV epitopes. Sets of epitopes recognized by HIV-1-speciﬁc
NAbs provide useful probes for further analysis into themech-
anistic details of cell fusion, and form a basis for deriving
therapeutically useful antibody-based HIV-1 fusion inhibitors.
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